GlaxoSmithKline is recalling prescription-only versions of its heartburn medicine Zantac globally after the U.S. Food and Drug Administration found "unacceptable" levels of a potential carcinogen in the drug, according to Channel News Asia.
Britain's medicines regulator said four prescription-only Zantac medicines, including a syrup, an injection and tablets in 150 and 300 milligram doses, would be recalled.
Over-the-counter Zantac products are produced by a different company.
The decision is "precautionary" as health regulators in the U.S. and U.K. continue to review the safety of products with ranitidine, a drug that reduces stomach acid.